Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Mesothelin Targeting IL12-Engineered CAR Memory-like NK Cells Demonstrate Promising Efficacy in Acute Myeloid Leukemia

Jieun Jang, Mila Stanojevic, Sara Piccinelli, Michal Sheffer, Grace Caroline Birch, Roman M. Shapiro, Maximilian Stahl, John Koreth, Catherine J. Wu, Robert J. Soiffer, Jerome Ritz, Mubin Tarannum, Rizwan Romee

Blood (2024) 144 (Supplement 1): 917.

https://doi.org/10.1182/blood-2024-204369

Published: 2024

Journal Articles

Natural Killer Cells Are Active Against Myeloma, Leukemia or Lymphoma Cells with Loss of Tumor Suppressor Genes

Olga Dashevsky, Sara Gandolfi, Olli Dufva, Ricardo De Matos Simoes, Jani Huuhtanen, Benjamin G. Barwick, Ryosuke Shirasaki, Michal Sheffer, Aidan Culhane, Jonathan D. Licht, Christine-Ivy Liacos, Evangelos Terpos, Efstathios Kastritis, Meletios Athanasios Dimopoulos, Lawrence H. Boise, Francisca Vazquez, Matti Kankainen, Satu Mustjoki, Constantine S Mitsiades

Blood (2023) 142 (Supplement 1): 6842.

https://doi.org/10.1182/blood-2023-189570

Published: 2023

Journal Articles

CTLA-4 Blockade Results in the Enrichment of Proliferative CD56 dim CD16 + NK Cells Following Infusion of Haploidentical Donor Memory-like Natural Killer Cells Plus IL-15 Superagonist in a Phase 1 Trial

Blood (2023) 142 (Supplement 1): 6850.

https://doi.org/10.1182/blood-2023-178362

Published: 2023

Journal Articles

Single-Cell Functional Genomics of Natural Killer Cell Interaction with Blood Cancers

Blood (2022) 140 (Supplement 1): 8343–8344.

https://doi.org/10.1182/blood-2022-167535

Published: 2022

Journal Articles

Functional Genomic Landscape of Natural Killer Cell Evasion in Multiple Myeloma

Sara Gandolfi, Olli Dufva, Jani Huuhtanen, Olga Dashevsky, Jay Klievink, Jonas Bouhlal, Michal Sheffer, Matti Kankainen, Ricardo De Matos Simoes, Satu Mustjoki, Constantine S. Mitsiades

Blood (2021) 138 (Supplement 1): 732.

https://doi.org/10.1182/blood-2021-153925

Published: 2021

Journal Articles

Functional Genomic and Immune Response Characterization of PTEN Loss: Therapeutic Implications for Myeloma

Olga Dashevsky, Ricardo De Matos Simoes, Benjamin G Barwick, Sara Gandolfi, Ryosuke Shirasaki, Michal Sheffer, Aedin Culhane, Richard WJ Groen, Aviad Tsherniak, Francisca Vazquez, Jonathan D. Licht, Lawrence H. Boise, Constantine S. Mitsiades

Blood (2021) 138 (Supplement 1): 1612.

https://doi.org/10.1182/blood-2021-153870

Published: 2021

Journal Articles

POU2AF1 As a Master Regulator of Oncogenic Transcription Factor Networks in Myeloma

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-142580

Published: 2020

Journal Articles

Use of Olfactory Receptor Genes As Controls for Genome-Scale CRISPR Functional Genomic Studies to Define Treatment Resistance Mechanisms

Olga Dashevsky, PhD, Ricardo De Matos Simoes, PhD, Ryosuke Shirasaki, MD, Michal Sheffer, PhD, Eugen Dhimolea, PhD, Sara Gandolfi, MD, Huihui Tang, PhD, Sondra L. Downey-Kopyscinski, PhD, Megan Bariteau, B.Sc., Jeffrey Sorrell, BA, Brian Glassner, PhD, John Doench, PhD, Larry H. Boise, PhD, Jonathan D. Licht, MD, Aedin Culhane, PhD, William C. Hahn, MD PhD, Francisca Vazquez, PhD, Aviad Tsherniak, PhD, Constantine S. Mitsiades, MD PhD

Blood (2020) 136 (Supplement 1): 36.

https://doi.org/10.1182/blood-2020-142651

Published: 2020

Journal Articles

Heterogeneity of Molecular Mechanisms Determining Blood Cancer Cell Lines Resistance to Natural Killer Cells in the Context of Tumor-Stromal Interactions: Insights from Studies of Pooled "DNA-Barcoded" Cell Line Panels

Sara Gandolfi, MD, Michal Sheffer, PhD, Olli Dufva, Khalid Saeed, Emily Lowry, Olga Dashevsky, PhD, Ryosuke Shirasaki, MD PhD, Ricardo De Matos Simoes, PhD, Jennifer Roth, Rizwan Romee, MD PhD, Satu Mustjoki, MD PhD, Constantine S. Mitsiades, MD PhD

Blood (2019) 134 (Supplement_1): 620.

https://doi.org/10.1182/blood-2019-130793

Published: 2019

Journal Articles

CRISPR Screens Identify Mechanisms of Natural Killer Cell Evasion across Blood Cancers

Olli Dufva, Khalid Saeed, Sara Gandolfi, MD, Michal Sheffer, PhD, Jay Klievink, Petri Pölönen, MSc, Tiina Hannunen, Mette Ilander, PhD, Pekka Ellonen, BSc, Matti Kankainen, PhD, Dean Anthony Lee, MD PhD, Constantine S. Mitsiades, MD PhD, Satu Mustjoki, MD PhD

Blood (2019) 134 (Supplement_1): 3597.

https://doi.org/10.1182/blood-2019-129837

Published: 2019

Journal Articles

Functional Characterization of Genes Driving Enhanced Biological Aggressiveness of Myeloma Cells: Identification of Novel and Understudied "Drivers" of Myeloma

Huihui Tang, PhD, Ryosuke Shirasaki, MD PhD, Ricardo De Matos Simoes, PhD, Sara Gandolfi, MD, Olga Dashevsky, PhD, Sondra L. Downey-Kopyscinski, PhD, Brian Glassner, PhD, Michal Sheffer, PhD, Megan Bariteau, BSc, John G Doench, PhD, Constantine S. Mitsiades, MD PhD

Blood (2019) 134 (Supplement_1): 313.

https://doi.org/10.1182/blood-2019-128919

Published: 2019

Journal Articles

Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins

Blood (2019) 134 (Supplement_1): 318.

https://doi.org/10.1182/blood-2019-130549

Published: 2019

Journal Articles

Systematic Characterization of Genes Representing Preferential Molecular Vulnerabilities for Myeloma Cells Compared to Other Neoplasias - Implications for the Biology and Therapeutic Targeting of Myeloma

Blood (2019) 134 (Supplement_1): 4407.

https://doi.org/10.1182/blood-2019-130901

Published: 2019

Journal Articles

CRISPR-Based Functional Genomics Studies Reveal Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins: Implications for Novel Therapeutics across Diverse Neoplasias

Blood (2018) 132 (Supplement 1): 1367.

https://doi.org/10.1182/blood-2018-99-116232

Published: 2018

Journal Articles

Identification of Molecular Markers of Tumor Cell Sensitivity and Resistance to Natural Killer Cells through Genome-Wide CRISPR Activation and CRISPR Editing Screens in Multiple Myeloma Cell Lines: Implications for Anti-Myeloma Immunotherapy

Sara Gandolfi, MD, Michal Sheffer, PhD, Emily Lowry, Olga Dashevsky, PhD, Ryosuke Shirasaki, MD PhD, Ricardo De Matos Simoes, PhD, Constantine S. Mitsiades, MD PhD

Blood (2018) 132 (Supplement 1): 1115.

https://doi.org/10.1182/blood-2018-99-118736

Published: 2018

Journal Articles

CRISPR Activation Screen for Drivers of MM Cell Proliferation

Huihui Tang, PhD, Ricardo De Matos Simoes, PhD, Ryosuke Shirasaki, MD PhD, Olga Dashevsky, PhD, Brian Glassner, PhD, Sondra L. Downey-Kopyscinski, PhD, Sara Gandolfi, MD, Michal Sheffer, PhD, Megan Bariteau, BSc, John G Doench, PhD, Constantine S. Mitsiades, MD PhD

Blood (2018) 132 (Supplement 1): 3197.

https://doi.org/10.1182/blood-2018-99-118712

Published: 2018

Journal Articles

CRISPR Activation Screen for HDAC Inhibitor Resistance

Blood (2018) 132 (Supplement 1): 3958.

https://doi.org/10.1182/blood-2018-99-119044

Published: 2018

Journal Articles

Functional Genomic Landscape of Genes with Recurrent Mutations in Multiple Myeloma

Ricardo De Matos Simoes, PhD, Ryosuke Shirasaki, MD PhD, Huihui Tang, PhD, Michal Sheffer, PhD, Olga Dashevsky, PhD, Sara Gandolfi, MD, Eugen Dhimolea, PhD, Megan Bariteau, BSc, Jonathan D. Licht, MD, Brian Glassner, PhD, Richard WJ Groen, PhD, Joan Levy, PhD, Daniel Auclair, PhD, Francisca Vazquez, PhD, Aviad Tsherniak, PhD, William C. Hahn, MD PhD, Aedin Culhane, PhD, Constantine S. Mitsiades, MD PhD

Blood (2018) 132 (Supplement 1): 189.

https://doi.org/10.1182/blood-2018-189

Published: 2018

Journal Articles

In Vivo Validation of Essential Genes for Myeloma Cells By CRISPR/Cas9 Studies in a Scaffold-Based System Engineered to Establish a "Humanized" Bone Marrow-like Microenvironment

Ryosuke Shirasaki, MD, Csikos Tamas, PhD, Geoffrey Matthews, PhD, Ricardo De Matos Simoes, PhD, Subhashis Sarkar, PhD, Olga Dashevsky, PhD, Hu Yiguo, PhD, Jeffrey Sorrell, BA, Michal Sheffer, PhD, Eugen Dhimolea, PhD, Megan Bariteau, Brian Glassner, PhD, Aedin Culhane, PhD, Richard WJ Groen, PhD, Constantine S. Mitsiades, MD PhD

Blood (2017) 130 (Supplement 1): 4414.

https://doi.org/10.1182/blood.V130.Suppl_1.4414.4414

Published: 2017

Journal Articles

Long-Term Interactions with Bone Marrow Stromal Cells Alter the Molecular Dependencies of Myeloma Cells: Insights from Genomewide CRISPR-Based Functional Genomic Screens

Sara Gandolfi, MD, Olga Dashevsky, PhD, Ricardo De Matos Simoes, PhD, Geoffrey Matthews, PhD, Ryosuke Shirasaki, MD PhD, Michal Sheffer, PhD, Constantine S. Mitsiades, MD PhD

Blood (2017) 130 (Supplement 1): 3028.

https://doi.org/10.1182/blood.V130.Suppl_1.3028.3028

Published: 2017

NARROW

Mesothelin Targeting IL12-Engineered CAR Memory-like NK Cells Demonstrate Promising Efficacy in Acute Myeloid Leukemia

Natural Killer Cells Are Active Against Myeloma, Leukemia or Lymphoma Cells with Loss of Tumor Suppressor Genes

CTLA-4 Blockade Results in the Enrichment of Proliferative CD56 dim CD16 + NK Cells Following Infusion of Haploidentical Donor Memory-like Natural Killer Cells Plus IL-15 Superagonist in a Phase 1 Trial

Single-Cell Functional Genomics of Natural Killer Cell Interaction with Blood Cancers

Functional Genomic Landscape of Natural Killer Cell Evasion in Multiple Myeloma

Functional Genomic and Immune Response Characterization of PTEN Loss: Therapeutic Implications for Myeloma

POU2AF1 As a Master Regulator of Oncogenic Transcription Factor Networks in Myeloma

Use of Olfactory Receptor Genes As Controls for Genome-Scale CRISPR Functional Genomic Studies to Define Treatment Resistance Mechanisms

Heterogeneity of Molecular Mechanisms Determining Blood Cancer Cell Lines Resistance to Natural Killer Cells in the Context of Tumor-Stromal Interactions: Insights from Studies of Pooled "DNA-Barcoded" Cell Line Panels

CRISPR Screens Identify Mechanisms of Natural Killer Cell Evasion across Blood Cancers

Functional Characterization of Genes Driving Enhanced Biological Aggressiveness of Myeloma Cells: Identification of Novel and Understudied "Drivers" of Myeloma

Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins

Systematic Characterization of Genes Representing Preferential Molecular Vulnerabilities for Myeloma Cells Compared to Other Neoplasias - Implications for the Biology and Therapeutic Targeting of Myeloma

CRISPR-Based Functional Genomics Studies Reveal Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins: Implications for Novel Therapeutics across Diverse Neoplasias

Identification of Molecular Markers of Tumor Cell Sensitivity and Resistance to Natural Killer Cells through Genome-Wide CRISPR Activation and CRISPR Editing Screens in Multiple Myeloma Cell Lines: Implications for Anti-Myeloma Immunotherapy

CRISPR Activation Screen for Drivers of MM Cell Proliferation

CRISPR Activation Screen for HDAC Inhibitor Resistance

Functional Genomic Landscape of Genes with Recurrent Mutations in Multiple Myeloma

In Vivo Validation of Essential Genes for Myeloma Cells By CRISPR/Cas9 Studies in a Scaffold-Based System Engineered to Establish a "Humanized" Bone Marrow-like Microenvironment

Long-Term Interactions with Bone Marrow Stromal Cells Alter the Molecular Dependencies of Myeloma Cells: Insights from Genomewide CRISPR-Based Functional Genomic Screens

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only